Dr Reddys Laboratories Stock EBITDA
| RDY Stock | USD 71.31 0.30 0.42% |
Dr Reddys Laboratories fundamentals help investors to digest information that contributes to Dr Reddys' financial success or failures. It also enables traders to predict the movement of RDY Stock. The fundamental analysis module provides a way to measure Dr Reddys' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Dr Reddys stock.
| Last Reported | Projected for Next Year | ||
| EBITDA | 125.1 B | 131.4 B |
RDY | EBITDA |
Dr Reddys Laboratories Company EBITDA Analysis
Dr Reddys' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Dr Reddys EBITDA | 108.78 B |
Most of Dr Reddys' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Dr Reddys Laboratories is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
RDY EBITDA Driver Correlations
Understanding the fundamental principles of building solid financial models for Dr Reddys is extremely important. It helps to project a fair market value of RDY Stock properly, considering its historical fundamentals such as EBITDA. Since Dr Reddys' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Dr Reddys' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Dr Reddys' interrelated accounts and indicators.
Click cells to compare fundamentals
RDY EBITDA Historical Pattern
Today, most investors in Dr Reddys Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Dr Reddys' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's ebitda growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Dr Reddys ebitda as a starting point in their analysis.
Dr Reddys EBITDA |
| Timeline |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
RDY Ebitda
Ebitda |
|
According to the company disclosure, Dr Reddys Laboratories reported earnings before interest,tax, depreciation and amortization of 108.78 B. This is much higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The ebitda for all United States stocks is significantly lower than that of the firm.
RDY EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Dr Reddys' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Dr Reddys could also be used in its relative valuation, which is a method of valuing Dr Reddys by comparing valuation metrics of similar companies.Dr Reddys is currently under evaluation in ebitda category among related companies.
Dr Reddys Current Valuation Drivers
We derive many important indicators used in calculating different scores of Dr Reddys from analyzing Dr Reddys' financial statements. These drivers represent accounts that assess Dr Reddys' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Dr Reddys' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 511.9B | 746.6B | 702.3B | 776.0B | 698.4B | 733.4B | |
| Enterprise Value | 531.9B | 762.0B | 721.2B | 783.7B | 705.4B | 740.6B |
Dr Reddys Institutional Holders
Institutional Holdings refers to the ownership stake in Dr Reddys that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Dr Reddys' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Dr Reddys' value.| Shares | Bank Of America Corp | 2023-12-31 | 562.6 K | Gqg Partners Llc | 2023-12-31 | 437 K | Lazard Asset Management Llc | 2023-12-31 | 347.1 K | Grantham, Mayo, Van Otterloo & Co., Llc | 2023-12-31 | 329.1 K | Schroder Investment Management Group | 2023-12-31 | 266.7 K | Mondrian Investment Partners Ltd | 2023-12-31 | 219 K | Acadian Asset Management Llc | 2023-12-31 | 211.3 K | Fisher Asset Management, Llc | 2023-12-31 | 205.3 K | Ameriprise Financial Inc | 2023-12-31 | 198.2 K | Goldman Sachs Group Inc | 2023-12-31 | 3.7 M | Blackrock Inc | 2023-12-31 | 3 M |
RDY Fundamentals
| Return On Equity | 0.21 | ||||
| Return On Asset | 0.12 | ||||
| Profit Margin | 0.19 % | ||||
| Operating Margin | 0.25 % | ||||
| Current Valuation | (40.77 B) | ||||
| Shares Outstanding | 166.52 M | ||||
| Shares Owned By Institutions | 15.03 % | ||||
| Number Of Shares Shorted | 625.76 K | ||||
| Price To Earning | 31.58 X | ||||
| Price To Book | 3.70 X | ||||
| Price To Sales | 0.04 X | ||||
| Revenue | 245.88 B | ||||
| Gross Profit | 113.84 B | ||||
| EBITDA | 108.78 B | ||||
| Net Income | 60.48 B | ||||
| Cash And Equivalents | 2.93 B | ||||
| Cash Per Share | 208.58 X | ||||
| Total Debt | 13.47 B | ||||
| Debt To Equity | 0.12 % | ||||
| Current Ratio | 1.98 X | ||||
| Book Value Per Share | 1,609 X | ||||
| Cash Flow From Operations | 58.87 B | ||||
| Short Ratio | 3.51 X | ||||
| Earnings Per Share | 3.75 X | ||||
| Price To Earnings To Growth | 4.71 X | ||||
| Target Price | 78.08 | ||||
| Number Of Employees | 25.86 K | ||||
| Beta | 0.34 | ||||
| Market Capitalization | 12.07 B | ||||
| Total Asset | 322.85 B | ||||
| Retained Earnings | 215.59 B | ||||
| Working Capital | 118.53 B | ||||
| Current Asset | 1.81 B | ||||
| Current Liabilities | 976 M | ||||
| Annual Yield | 0.01 % | ||||
| Five Year Return | 0.72 % | ||||
| Net Asset | 322.85 B | ||||
| Last Dividend Paid | 40.0 |
About Dr Reddys Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Dr Reddys Laboratories's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Dr Reddys using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Dr Reddys Laboratories based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Dr Reddys Laboratories offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Dr Reddys' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Dr Reddys Laboratories Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Dr Reddys Laboratories Stock:Check out Dr Reddys Piotroski F Score and Dr Reddys Altman Z Score analysis. Note that the Dr Reddys Laboratories information on this page should be used as a complementary analysis to other Dr Reddys' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Complementary Tools for RDY Stock analysis
When running Dr Reddys' price analysis, check to measure Dr Reddys' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dr Reddys is operating at the current time. Most of Dr Reddys' value examination focuses on studying past and present price action to predict the probability of Dr Reddys' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dr Reddys' price. Additionally, you may evaluate how the addition of Dr Reddys to your portfolios can decrease your overall portfolio volatility.
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine |
Is Dr Reddys' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dr Reddys. If investors know RDY will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dr Reddys listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.103 | Dividend Share 40 | Earnings Share 3.75 | Revenue Per Share 272.4618 | Quarterly Revenue Growth 0.066 |
The market value of Dr Reddys Laboratories is measured differently than its book value, which is the value of RDY that is recorded on the company's balance sheet. Investors also form their own opinion of Dr Reddys' value that differs from its market value or its book value, called intrinsic value, which is Dr Reddys' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dr Reddys' market value can be influenced by many factors that don't directly affect Dr Reddys' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Dr Reddys' value and its price as these two are different measures arrived at by different means. Investors typically determine if Dr Reddys is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dr Reddys' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.